住院期间唑来膦酸治疗联合骨科与骨折联络服务提高骨质疏松治疗率
该单中心观察性随访研究纳入麻省总医院2016年2月至2019年12月收治的脆性骨折患者,骨科服务系统会诊骨折联络服务(FLS),对可能无法及时门诊随访者在骨折住院期间给予唑来膦酸(ZA)。与基线(8-11%)和参考(5-20%)率相比,FLS与骨科整合联合住院ZA使符合条件且治疗状态确认患者的药物治疗率提高至70%(412/589),住院ZA不影响平均住院时长和30天再入院率,但37.9%(471/1240)患者治疗状态因失访未知。
要点
- FLS与骨科整合联合住院ZA使脆性骨折患者骨质疏松药物治疗率达70%(412/589)。
- 住院期间给予ZA不影响平均住院时长和30天再入院率。
- 37.9%(471/1240)患者治疗状态因缺乏或未知随访而未知。
核心结论
- 整合FLS与骨科服务并住院期间给予ZA,提高了常面临门诊随访障碍的脆性骨折患者的骨质疏松药物治疗率。
研究设计与样本
- 单中心、观察性、随访研究,纳入2016年2月至2019年12月收治于麻省总医院的脆性骨折患者。
- 骨科服务收治的脆性骨折患者系统会诊麻省总医院骨折联络服务(FLS),初始门诊随访与骨科术后随访一同安排。
- 有未能及时门诊随访风险的患者在索引骨折住院期间给予唑来膦酸(ZA)。
主要发现
- 与基线(8-11%)和参考(5-20%)率相比,FLS与骨科整合联合住院ZA使符合条件且治疗状态确认患者的药物治疗率提高至70%(412/589)。
- 住院ZA给药不影响平均住院时长,也不影响30天再入院率。
- 37.9%(471/1240)研究患者的治疗状态因缺乏或未知随访而未知。
局限性
- 37.9%(471/1240)研究患者的治疗状态因缺乏或未知随访而未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Fragility fractures increase risks for future fractures, morbidity, and mortality. Available pharmacotherapy for underlying osteoporosis is safe and effective but underused. OBJECTIVE: To improve pharmacotherapy rate representing secondary prevention of osteoporotic fractures. METHODS: This single-center, observational, follow-up study included patients with fragility fractures admitted to the Massachusetts General Hospital between February 2016 and December 2019. For patients admitted to the orthopedics service with fragility fracture, the Massachusetts General Hospital Fracture Liaison Service (FLS) was systematically consulted. Initial outpatient follow-up with FLS was established in conjunction with the orthopedic postoperative follow-up visit. Patients at risk for failing timely outpatient follow-up were administered zoledronic acid (ZA) during the index fracture hospitalization. The main outcome measures were percentage of patients with fragility fracture(s) started on pharmacotherapy for osteoporosis and average length of stay and 30-day readmission rate of patients treated with ZA. RESULTS: Compared with baseline (8-11%) and reference (5-20%) rates, integration of FLS to the orthopedics service, along with appropriate inpatient administration of ZA, increased the pharmacotherapy rate to 70% (412/589) among eligible patients with verified treatment status. Inpatient ZA administration neither affected the average length of stay nor 30-day readmission rate. Treatment status of 37.9% (471/1240) of the study patients remained unknown due to lack of or unknown follow-up. CONCLUSION: Integration of a FLS and orthopedics services along with inpatient ZA administration improved the osteoporosis pharmacotherapy rate among patients with fragility fracture(s) who often had obstacles for outpatient follow-up.
引用
- Fan W, Machado M, Leder BZ, et al. Inpatient Zoledronic Acid and Integrated Orthopedic and Fracture Liaison Services Improve Osteoporosis Treatment Rates. J Clin Endocrinol Metab. 2022. PMID: 36056816. doi:10.1210/clinem/dgac508
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。